A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

NCT03499704 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Pioglitazone + Alogliptin
DRUG: Alogliptin
DRUG: Metformin
DRUG: Dapagliflozin

Sponsor

Celltrion Pharm, Inc.